Vadim Pedchenko
Faculty Member
Last active: 4/25/2016

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN. Ooi JD, Chang J, O'Sullivan KM, Pedchenko V, Hudson BG, Vandenbark AA, Fugger L, Holdsworth SR, Kitching AR (2013) J Am Soc Nephrol 24(3): 419-31
    › Primary publication · 23411782 (PubMed) · PMC3582203 (PubMed Central)
  2. Enhancing integrin α1 inserted (I) domain affinity to ligand potentiates integrin α1β1-mediated down-regulation of collagen synthesis. Shi M, Pedchenko V, Greer BH, Van Horn WD, Santoro SA, Sanders CR, Hudson BG, Eichman BF, Zent R, Pozzi A (2012) J Biol Chem 287(42): 35139-52
    › Primary publication · 22888006 (PubMed) · PMC3471707 (PubMed Central)
  3. Peroxidasin forms sulfilimine chemical bonds using hypohalous acids in tissue genesis. Bhave G, Cummings CF, Vanacore RM, Kumagai-Cresse C, Ero-Tolliver IA, Rafi M, Kang JS, Pedchenko V, Fessler LI, Fessler JH, Hudson BG (2012) Nat Chem Biol 8(9): 784-90
    › Primary publication · 22842973 (PubMed) · PMC4128002 (PubMed Central)
  4. Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues. Chetyrkin S, Mathis M, Pedchenko V, Sanchez OA, McDonald WH, Hachey DL, Madu H, Stec D, Hudson B, Voziyan P (2011) Biochemistry 50(27): 6102-12
    › Primary publication · 21661747 (PubMed) · PMC3140462 (PubMed Central)
  5. Sulphilimine cross-links in Goodpasture's disease. Vanacore R, Pedchenko V, Bhave G, Hudson BG (2011) Clin Exp Immunol : 4-6
    › Primary publication · 21447121 (PubMed) · PMC3095855 (PubMed Central)
  6. Goodpasture's disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis. Pedchenko V, Vanacore R, Hudson B (2011) Curr Opin Nephrol Hypertens 20(3): 290-6
    › Primary publication · 21378566 (PubMed) · PMC3159420 (PubMed Central)
  7. Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes. Parkin JD, San Antonio JD, Pedchenko V, Hudson B, Jensen ST, Savige J (2011) Hum Mutat 32(2): 127-43
    › Primary publication · 21280145 (PubMed) · PMC4800984 (PubMed Central)
  8. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG (2010) N Engl J Med 363(4): 343-54
    › Primary publication · 20660402 (PubMed) · PMC4144421 (PubMed Central)
  9. MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Rebustini IT, Myers C, Lassiter KS, Surmak A, Szabova L, Holmbeck K, Pedchenko V, Hudson BG, Hoffman MP (2009) Dev Cell 17(4): 482-93
    › Primary publication · 19853562 (PubMed) · PMC2768621 (PubMed Central)
  10. A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes. Vanacore RM, Ham AJ, Cartailler JP, Sundaramoorthy M, Todd P, Pedchenko V, Sado Y, Borza DB, Hudson BG (2008) J Biol Chem 283(33): 22737-48
    › Primary publication · 18499662 (PubMed) · PMC2504875 (PubMed Central)
  11. Human podocytes adhere to the KRGDS motif of the alpha3alpha4alpha5 collagen IV network. Borza CM, Borza DB, Pedchenko V, Saleem MA, Mathieson PW, Sado Y, Hudson HM, Pozzi A, Saus J, Abrahamson DR, Zent R, Hudson BG (2008) J Am Soc Nephrol 19(4): 677-84
    › Primary publication · 18235087 (PubMed) · PMC2390958 (PubMed Central)
  12. Mammalian collagen IV. Khoshnoodi J, Pedchenko V, Hudson BG (2008) Microsc Res Tech 71(5): 357-70
    › Primary publication · 18219669 (PubMed) · PMC4788096 (PubMed Central)
  13. Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals. Fox MA, Sanes JR, Borza DB, Eswarakumar VP, Fässler R, Hudson BG, John SW, Ninomiya Y, Pedchenko V, Pfaff SL, Rheault MN, Sado Y, Segal Y, Werle MJ, Umemori H (2007) Cell 129(1): 179-93
    › Primary publication · 17418794 (PubMed)
  14. A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. Chen L, Hellmark T, Pedchenko V, Hudson BG, Pusey CD, Fox JW, Bolton WK (2006) J Am Soc Nephrol 17(11): 3076-81
    › Primary publication · 17005930 (PubMed)
  15. Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3. Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, Hudson BG, Zent R (2006) J Biol Chem 281(30): 20932-9
    › Primary publication · 16731529 (PubMed)
  16. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Pedchenko VK, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, Hudson BG, Voziyan PA (2005) Diabetes 54(10): 2952-60
    › Primary publication · 16186398 (PubMed)
  17. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. Pedchenko V, Zent R, Hudson BG (2004) J Biol Chem 279(4): 2772-80
    › Primary publication · 14610079 (PubMed)
  18. Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis. Imagawa W, Pedchenko VK, Helber J, Zhang H (2002) J Steroid Biochem Mol Biol 80(2): 213-30
    › Primary publication · 11897505 (PubMed)
  19. In vivo inhibition of keratinocyte growth factor receptor expression by estrogen and antagonism by progesterone in the mouse mammary gland. Imagawa W, Pedchenko VK (2001) J Endocrinol 171(2): 319-27
    › Primary publication · 11691652 (PubMed)
  20. Pattern of expression of the KGF receptor and its ligands KGF and FGF-10 during postnatal mouse mammary gland development. Pedchenko VK, Imagawa W (2000) Mol Reprod Dev 56(4): 441-7
    › Primary publication · 10911393 (PubMed)
  21. Attenuation and loss of hormonal modulation of KGF (FGF-7)/KGF receptor expression and mitogenesis during mammary tumor progression. Imagawa W, Pedchenko VK, Helber J, Xing C (2000) J Cell Physiol 184(2): 222-8
    › Primary publication · 10867647 (PubMed)
  22. Estrogen treatment in vivo increases keratinocyte growth factor expression in the mammary gland. Pedchenko VK, Imagawa W (2000) J Endocrinol 165(1): 39-49
    › Primary publication · 10750034 (PubMed)
  23. Mammogenic hormones differentially modulate keratinocyte growth factor (KGF)-induced proliferation and KGF receptor expression in cultured mouse mammary gland epithelium. Pedchenko VK, Imagawa WT (1998) Endocrinology 139(5): 2519-26
    › Primary publication · 9564867 (PubMed)
  24. Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Shah GV, Pedchenko V, Stanley S, Li Z, Samson WK (1996) Endocrinology 137(5): 1814-22
    › Primary publication · 8612519 (PubMed)
  25. Lysophosphatidylcholine specifically stimulates plasma membrane H(+)-ATPase from corn roots. Pedchenko VK, Nasirova GF, Palladina TA (1990) FEBS Lett 275(1-2): 205-8
    › Primary publication · 2148158 (PubMed)